Pharma BD Deal Intelligence

Boehringer Ingelheim International GmbH / Hanmi Pharmaceutical Co., Ltd. (HM61713 program)

2015 · Licensing/Option · $730M · Terminated

Boehringer Ingelheim acquired exclusive ex-Korea/China/Hong Kong rights to Hanmi's third-generation EGFR TKI HM61713 for $50M upfront and up to $680M in milestones plus tiered double-digit royalties. Boehringer terminated the deal September 30, 2016 following clinical safety signals (interstitial lung disease deaths).

Key facts

• Announced Jul 28, 2015
• Closed Jul 28, 2015
• Deal value $730M
• Deal type Licensing/Option
• Therapeutic area T790M-mutant EGFR non-small cell lung cancer (NSCLC)
• Indications T790M-mutant EGFR non-small cell lung cancer (NSCLC)
• Key assets HM61713 (olmutinib / BI 1482694)
• Mechanism Third-generation oral EGFR T790M-mutant selective tyrosine kinase inhibitor

← Browse all deals  ·  How we score deals